Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663 by Jian, Pan et al.
RESEARCH Open Access
Retinoic acid induces HL-60 cell differentiation via
the upregulation of miR-663
Pan Jian
1,3, Zhao Wen Li
1, Tao Yan Fang
1, Wang Jian
1, Zhou Zhuan
2, Liao Xin Mei
3, Wu Shui Yan
1 and Ni Jian
1,3*
Abstract
Background: Differentiation of the acute myeloid leukemia (AML) cell line HL-60 can be induced by all trans-
retinoic acid (ATRA); however, the mechanism regulating this process has not been fully characterized.
Methods: Using bioinformatics and in vitro experiments, we identified the microRNA gene expression profile of
HL-60 cells during ATRA induced granulocytic differentiation.
Results: Six microRNAs were upregulated by ATRA treatment, miR-663, miR-494, miR-145, miR-22, miR-363* and
miR-223; and three microRNAs were downregulated, miR-10a, miR-181 and miR-612. Additionally, miR-663
expression was regulated by ATRA. We used a lentivirus (LV) backbone incorporating the spleen focus forming
virus (SFFV-F) promoter to drive miR-663 expression, as the CMV (Cytomegalovirus) promoter is ineffective in some
lymphocyte cells. Transfection of LV-miR-663 induced significant HL-60 cell differentiation in vitro.
Conclusions: Our results show miR-663 may play an important role in ATRA induced HL-60 cell differentiation.
Lentivirus delivery of miR-663 could potentially be used directly as an anticancer treatment in hematological
malignancies
Background
Differentiation of the acute myeloid leukemia (AML)
cell line HL-60 can be induced by all trans-retinoic acid
(ATRA); however, the mechanism regulating this pro-
cess is not yet fully understood [1]. Erkel et al. reported
that growth arrest and induction of differentiation of
HL-60 cells in response to Sch 52900 is due to induc-
tion of the cell cycle inhibitor p21WAF, and inhibition
of the extracellular signal-regulated kinase (ERK) signal-
ing pathway, leading to activation of the transcription
factor AP-1 [2]. Microarray analysis has shown ATRA
can induce upregulation of genes involved in differentia-
tion, the oxidase activation pathway and adhesion
molecules. In HL-60 cells, ATRA treatment induces dif-
ferential expression of a variety of genes from several
pathways, including the differentiation pathway [3-5]. So
far, few studies have focused on expression of micro-
RNAs during HL-60 differentiation, and the expression
profiles of human miRNAs during cell differentiation
remain largely unknown.
This study analyzed the microRNA expression profile
in HL-60 cells treated with ATRA. to investigate
whether ATRA can induce growth arrest via upregula-
tion of miR-663 expression, which has been linked to
modulation of the cell cycle and mitotic growth arrest
[6]. Our results showed both ATRA and miR-663 can
significantly inhibit HL-60 cell proliferation and induce
differentiation.
MicroRNAs regulate the expression of genes involved
in the control of development, proliferation, apoptosis,
and stress responses [7-9]. Analysis of microRNA
expression and function during hematopoiesis has unra-
veled the existence of several complex regulatory loops
by which microRNAs fine-tune hematopoietic differen-
tiation and proliferation. The expression profiles of miR-
142 [10,11], miR-181 [12-14] and miR-223 [14-16] have
been described in B cells, T cells, monocytes, granulo-
cytes and erythroid cells in murine hematopoiesis. Ecto-
pic expression of these miRNAs dramatically alters the
proportion of differentiated murine hematopoietic cell
lineages in vitro and in vivo [17-21]. This suggests miR-
NAs can play an important lineage-specific role in
mammalian cell differentiation. In humans, miR-107 and
miR-223 are upregulated during ATRA induced
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are postulated to downregulate their target gene NFI-A,
and mediate a regulatory loop during cell differentiation
[22]. This data suggests miRNAs can function as onco-
genes or tumor suppressors, and play important roles in
the genesis of leukemia. Using a bioinformatic approach
followed by in vitro experiments, we identified the
microRNA gene expression profile of the AML cell line
HL-60 during ATRA induced granulocytic differentia-
tion. We further demonstrated that miR-663 expression
level is regulated by ATRA.
Lentiviral technology represents a powerful method to
genetically modify leukemia cells. We chose to use a viral
expression backbone driven by the spleen focus forming
virus (SFFV-F) promoter, as the CMV (Cytomegalovirus)
promoter has been shown to be ineffective in some lym-
phocyte cells. We focused on miR-663 as a candidate
molecule which is important for HL-60 cell differentia-
tion. The virus expressing the miR-663 precursor was
compared to a control mock virus containing GFP. Lenti-
virus transfection showed LV-miR-663 significantly
induces HL-60 cell differentiation in vitro.m i R - 6 6 3m a y
play important role in the differentiation of HL-60 cells
treated with ATRA and miR-663 lentivirus could poten-
tially be used directly as an anticancer treatment in he.
Methods
2.1 Cell line and reagents
HL-60 cells were obtained from our own laboratory.
ATRA, RPMI 1640, MTT, DMSO, TPA and NBT were
obtained from Sigma Co. DMEM was obtained from
Invitrogen. PCR primers were synthesized by Shanghai
Sangon Biotechnology Co. Ltd. PE-conjugated CD11b
(ITGAM integrin alpha M) antibody was purchased
from Pharmingen Co.
2.2 Cell culture and induction
HL-60 cells were cultured in RPMI 1640 standard med-
ium with 2 mmol/L L-glutamine supplemented with
10% heat-inactivated fetal calf serum, 100 U/ml penicil-
lin and 100 μg / m ls t r e p t o m y c i na t3 7 ° Ci n5 %C O 2.
Exponentially growing cells (approximately 1 × 10
7)
were incubated with 0.1 μmol/L ATRA, 0.1% alcohol or
untreated RPMI 1640 for 1 to 3 days.
2.3 MTT proliferation assay
Cell proliferation was determined using the MTT
(methyl thiazolyl tetrazolium) assay. HL-60 cells (5 ×
10
5/well in 96-well plates) were incubated with
0.1 μmol/L ATRA [23], 0.1% alcohol or untreated RPMI
1640 for 24 to 72 h, then 10 μl5m g / m 1M T Tw a s
added to each well for 4 h. The reaction was stopped by
addition of 150 μl DMSO and absorbance (A) at
490 nm was determined on a plate reader (Bio-Rad).
Each group was analyzed in triplicate samples. Cell inhi-
bition rate = 100% × (control group A values -experi-
mental group A values)/control group A values.
2.4 NBT and CD11b differentiation assays
Differentiation of HL-60 cells was assessed using the
NBT (nitroblue tetrazolium) reduction test and flow
cytometry detection of the cellular surface differential
antigen CD11b. Briefly, 100 μl1×1 0
6/m1 HL-60 cells
in 96-well plates were incubated with 0.1 μ mol/L
ATRA [23] for 1 to 3 days. RPMI 1640 was used as a
blank control and 0.1% alcohol was used as the solvent
control. 100 μl 1 mg/ml NBT and 200 μl1m g / m lT P A
were added to each well and incubated at 37°C in 5%
CO2 for 1 h, after which the cells were centrifuged for
5 min and then subjected to Wright’s staining. When
NBT is phagosomed by cells, the intracellular dye con-
verts to insoluble blue formazan crystals [24]. The num-
ber of positive cells containing blue formazan crystals
was determined from two hundred cells using micro-
scopy with an oil immersion objective. For detection of
the cell differentiation antigen CD11b [25,26], 1 × 10
6
cells were washed twice with PBS, incubated with PE-
conjugated CD11b antibody or PE-conjugated IgG1iso-
type control antibody at 4°C for 30 min and analyzed by
flow cytometry using a FACScan flow cytometer and
Cell Quest software (Becton Dickinson, Mountain View,
CA). The expression rate of CD11b positive cells was
determined from 1 × 10
4 cells for each group.
2.5 MicroRNA expression profiling
MicroRNAs were extracted using the mirVana miRNA
isolation kit (AM1560, Applied Biosystems, USA). Sam-
ples which were successfully isolated were analyzed
using an Agilent miRNA Chip version 10.0 at the
Microarray Core Facility, Baylor College of Medicine,
USA. In total, 637 images were acquired, calculated,
normalized and filtering of signal intensity for each spot
and batch-effect adjustment was performed. A total of
235 microRNA probes met the filtering criteria for sub-
sequent analysis using significance analysis of microar-
rays (SAM, Version 3.0, 2007, http://www-stat.stanford.
edu/~tibs/SAM/).
2.6 miRNA extraction and real-time quantitative PCR
(qRT-PCR) assays
Extraction of miRNA was performed using the mirVana
miRNA isolation kit and TaqMan miRNA assays were
used to detect and quantify mature miR-663 as pre-
viously described [6]. Briefly, total RNA was reverse
transcribed using the Reverse Transcription Kit (Applied
B i o s y s t e m sI n c . ,C A ) ,a c c o r ding to the manufacturer’s
instructions. The RT primers were: U6 5’-CGCTTCACG
AATTTGCGTGTCAT-3’ and mir-663 5’-GTCGTATCC
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ACGACGCGGTCC-3’. The PCR primers used to quan-
tify U6 expression were:
F: 5’-GCTTCGGCAGCACATATACTAAAAT-3’ and
R: 5’-CGCTTCACGAATTTGCGTGTCAT-3’ and for
mir-663 were: F: 5’-GTGCGTGTCGTGGAGTCG-3’
and R: 5’-TTTAGGCGGGGCG-3’. mir-663 expression
was normalized to endogenous U6 expression using the
SDS relative quantification software (Applied Biosystems
Inc, USA).
2.7 MicroRNA lentiviral expression constructs and
lentivirus production
The lentiviral vector expressing miR-663 has been pre-
viously described [6]. Briefly, an approximately 250 bp
fragment containing the human miR-663 precursor hair-
pin loops was amplified by PCR using using primers
flanked by BamHIa n dXhoI sites at the 5’ and 3’ ends,
and cloned into the pDrive cloning vector (Qiagen)
under the control of the RNA Pol III mouse U6 promo-
ter. Positive clones were confirmed by sequencing and
subcloned into the pHR’ SINcPPT SFFV-WPRE vector
under the control of the SFFV promoter. The GFP
virus, driven by the SFFV promoter, has also been pre-
viously described [27]. The vector plasmids, gag-pol
plasmid (pD8.91) and the VSVG envelope encoding
plasmid (pMD2-G), were amplified in E.Coli and puri-
fied using the Endofree Maxiprep Kit (Qiagen). 13 μg
transfer vector, 10 μg pD8.91 and 6 μgp M D 2 - Gw a s
mixed with 1.5 mL 0.25 M CaCl2 (Sigma) and added to
1.5 mL 2 × HEPES (Sigma) and mixed while bubbling
for 20 min to allow a precipitate to form. This was then
added to a 175 cm
2 flask of approximately 60% conflu-
ent 293T cells containing 20 mL DMEM supplemented
with 10% fetal calf serum, 100 U/mL penicillin, 100 μg/
mL streptomycin and 2 mM glutamine and incubated
for 48 h at 37°C in 5% CO2. The supernatant was cen-
trifuged at 1,700 g for 10 min to pellet cell debris, and
ultracentrifuged at 121,603 g for 2 h. The pellet contain-
ing concentrated virus was resuspended in DMEM with-
out supplements and stored at -80°C.
2.8 Statistical analysis
All data are presented as mean ± SD. Statistical analysis
was performed using SPSS (Chicago, IL). Student’s two-
tailed t-tests were used to compare groups and p ≤ 0.05
was considered significant.
Results and discussion
ATRA inhibited HL-60 cell proliferation (Figure 1A and
1B). After incubation with 0.1 μmol/L ATRA, the inhibi-
tion rates of HL-60 cells determined using the MTT
assay were 32.5 ± 9.3%, 47.4 ± 11.3% and 57.2 ± 12.4%
at 1, 2 or 3 days respectively, compared with the solvent
control group, p < 0.01. These results indicate ATRA
can inhibit HL-60 proliferation in a time-dependent
manner.
ATRA also induced HL-60 mature granulocyte cell dif-
ferentiation (Figures 1C and 1D). Treatment with ATRA
for 1 to 3 days significantly increased the number of HL-
60 cells expressing CD11b. After 1, 2 and 3 days the
expression rates of CD11b in ATRA treated cells were
41.2 ± 9.1%, 57.4 ± 11.4% and 67.2% ± 12.4% respectively,
compared with the solvent control group (0.56 ± 0.21%,
p < 0.01). The percentage of NBT positive cells in HL-60
cells treated with ATRA for 1, 2 or 3 days (Figure 1E)
was 12.5%±9.1%, 27.4% ± 10.3% and 47.2% ± 10.4%
respectively, compared with the solvent control group
4.31% ± 2.3%, p < 0.01, providing further evidence that
ATRA promotes HL-60 cell differentiation.
A miRNA microarray identified the expression of several
microRNAs significantly changed in HL-60 cells during
ATRA-induced differentiation. Significance analysis of
microarrays (Figure 2A) was used to identify miRNAs
whose expression was altered more than 2 fold in response
to treatment with ATRA for 24-72 h, and the differentially
expressed microRNAs are listed in Figure 2B.
We confirmed miR-663 was significantly upregulated
by ATRA treatment using TaqMan mircoRNA qRT-
PCR assays. MiR-663 is a challenging molecule to
amplify using PCR as the microRNA precursor consists
o fah i g h l ys t a b l eh a i r p i nd u et oG Cb a s ep a r i n g ;
however, novel technologies have been developed to
successfully amplify and qua n t i f yt h em a t u r em i R - 6 6 3 .
Real-time PCR has become the gold standard of nucleic
acid quantification due the high specificity and sensitiv-
ity and technological advancements have enabled quan-
tification of microRNAs in a comparable manner to
mRNAs. The time course of mature miR-663 expression
determined by qRT-RCR (Figure 3A) indicated miR-663
was significantly upregulated in ATRA treated HL-60
cells. After 72 h, expression of miR-633 in the ATRA
treated group was 6.93 ± 1.31 compared with the con-
trol group 1.17 ± 0.24, Figure 3B, p < 0.01.
Recombinant vectors based on retroviruses, including
both onco-retroviruses and lentiviruses, remain the only
choice to efficiently and stably transduce leukemia cells.
Lentiviruses (LV) offer several advantages. Firstly, LV
can transduce both dividing and non-dividing cells
including freshly isolated hematopoietic stem cells and
T cells in blood. Secondly, LV can accommodate various
transcriptional promoters, either ubiquitous or cell-
specific; and thirdly, self-inactivating safety modifica-
tions, which permanently disable viral promoters within
the viral long-terminal repeat region after integration,
enables control of transgene expression in the targeted
cells solely by internal promoters. We used a SFFV pro-
moter lentiviral backbone as the CMV promoter is
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a lentiviral construct into a cell line for the first time, a
range of volume or MOI (multiplicities of infection)
should be tested. MOIs of 1, 10 and 100 were used to
determine the optimal transduction efficiency using a
control plasmid. High transduction efficiency was
observed in the MOI 100 group, where approximately
80% of the cells expressed GFP (Figure 4A).
Transfection of the miR-663 lentivirus, LV-miR-663,
inhibited HL-60 proliferation in a time-dependent man-
ner. MTT assays indicated inhibition rates were 34.2 ±
13.1%, 45.2 ± 24.5% and 53.2 ± 21.3% at 1, 2 and 3 days
respectively, compared with the mock transfected group,
p < 0.01, Figure 4B. LV-miR-663 also induced HL-60
differentiation and lead to a significant increase in the
rate of CD11b expression, indicating mature granulocyte
differentiation.
ATRA is the acid form of vitamin A, and can inhibit
proliferation and induce differentiation in tumor cells.
As a physiological inducer of differentiation, ATRA
has been successfully applied in the treatment of hema-
tological malignancies and has become a model of dif-
ferentiation therapy (8). It has been demonstrated that
PML-RARa is able to influence transcription of several
miRNA genes [10,13]. As the expression of these miR-
NAs is restored by ATRA, our results suggest the effects
of successful clinical protocols to eradicate APL cells
m a yb em e d i a t e d ,i np a r t ,b ya f f e c t i n gm i c r o R N A
expression. These findings also indicate that ATRA may
also indirectly affect gene transcription through the abil-
ity of microRNAs to regulate of post-transcriptional
mRNA processing.
In the present study, we characterized the expression
profile of microRNAs during HL-60 ATRA-induced
Figure 1 ATRA inhibits proliferation and induces differentiation in HL-60 cells. (A) Morphology of HL-60 cells treated with 0.1 μmol/L ATRA
or 0.1% alcohol at 48 hours. (B) Cell inhibition rates in ATRA and 0.1% alcohol treated HL-60 cells at 24-72 hours, determined using the MTT
assay. Each group was assayed in triplicate. Cell inhibition rate was calculated as 100% × (control group A values -experimental group A values)/
control group A values. (C-E) HL-60 cell differentiation was assessed using CD11b and the NBT reduction test. (C-D) CD11b flow cytometry
analysis of cells treated with ATRA or 0.1% alcohol. The expression rate was determined as the number of CD11b positive cells in 1 × 10
4 cells.
(E) NBT analysis of HL-60 cells treated with ATRA or 0.1% alcohol. Two hundred cells were observed and positive cells with blue formazan
crystals were counted by microscopy, **p < 0.01.
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ber of microRNAs upregulated and downregulated in a
time-dependent manner. Our findings are consistent
with the previous observations of Croce CM, Norrild B
and Barrera G [28-30]. We also observed that miR-663
is upregulated in response to ATRA treatment in HL-60
cells, which is the first report of the involvement of
miR-663 in ATRA-induced differentiation. In HL-60
cells, Pizzimenti et al. reported miR-663 was upregulated
by 4-Hydroxynonenal (HNE) treatment [30] and Kasa-
shima et al. reported miR-663 was upregulated during
12-O-tetradecanoylphorbol-13-acetate (TPA) induced
differentiation [31]. Lutherburrow et al. reported expres-
sion of miR-663 is higher in M1 than M5 AML patients
and hypothesized it may potentially be involved in
blocking the differentiation of M1 blasts, and conse-
quently monocytic differentiation [32].
M i R - 6 6 3s e e m st oh a v ed u a lf u n c t i o n s ,a n dt h er o l ei t
mediates varies in different experimental models. In
human THP-1 monocytic cells and human blood mono-
cytes, resveratrol upregulates miR-663 expression [28].
MiR-663 is an oscillatory shear (OS) sensitive microRNA,
Figure 2 MicroRNA expression in HL-60 cells during ATRA-induced differentiation. The microRNA profile in HL-60 cells treated with ATRA
or 0.1% alcohol was determined using a microRNA microarray as described in the materials and methods (A) significance analysis of microarrays
of differentially regulated microRNAs in ATRA treated cells. (B) List of differentially expressed microRNA and their fold expression changes.
Figure 3 ATRA treatment significantly upregulates miR-663 in HL-60 cells. (A) TaqMan qRT-PCR miRNA assays were used to quantify the
time course of mature miR-663 expression in HL-60 cells treated with ATRA. Expression was normalized to endogenous U6 expression. (B)
Summary of TaqMan qRT-PCR miRNA assay results showing miR-663 was significantly upregulated in ATRA treated cells. At 72 h, mir-633
expression in ATRA treated cells (6.93 ± 1.31) was significantly increased compared to cells treated with 1% ethanol (1.17 ± 0.24, p < 0.01).
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generated. (A) Multiplicities of infection (MOI) of 1, 10 and 100 were used to determine optimal transduction efficiency in HL-60 cells using a
control GFP-expressing lentivirus; GFP was detected in approximately 80% cells in the MOI 100 group. (B) MTT assays indicated the inhibition
rates of HL-60 transfected with LV-miR-663 were 34.2 ± 13.1%, 45.2 ± 24.5% and 53.2 ± 21.3% at 1, 2 and 3 days, respectively, compared with
mock transfected cells, p < 0.01. These results indicate miR-663 expression inhibits HL-60 proliferation in a time-dependent manner. (C) miR-663
induces HL-60 differentiation to mature granulocytes. In cells transfected with LV-miR-663 expression of the differentiation marker CD11b was
increased significantly and after 1, 2 or 3 days the expression rates of CD11b were 21.2 ± 9.3%, 27.4 ± 12.5% and 33.2% ± 12.4% respectively in
LV-miR-663 transfected cells, compared with the mock transfected cells (0.56 ± 0.21%, p < 0.01).
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responses by mediating the expression of inflammatory
genes in HUVECs [33]. Downregulation of miR-663 in
tumor cells may contribute to aberrant cell hyperplasia,
leading to the development of gastric cancer [6].
Thousands of miR-663 target genes have been pre-
dicted by bioinformatic analysis and interestingly, most
are transcription factors of AP-1 [28]. In THP-1 cells,
miR-663 decreases endogenous activator protein-1 (AP-
1) activity and impairs lipopolysaccharide (LPS) induced
upregulation of AP-1 by, in part, by directly targeting
the Jun B and Jun D transcripts. Dose dependent down-
regulation of AP-1 activity and Jun B levels by resvera-
trol are miR-663 dependent. The specific targeting of
genes encoding a subset of AP-1 factors by mir-633,
such as Jun B and Jun D, may possibly explain some of
the anti-leukemia function of ATRA. Bioinformatic tools
have predicted TGF-b is also a target gene of miR-663,
w h i c hi so fi n t e r e s ta sT B F - b is an important molecule
with roles in many signaling pathways. These findings
indicate miR-663 expression is upregulated during
ATRA-induced differentiation, and lentivirus expressing
miR-663 can significantly induce HL-60 differentiation.
This study demonstrates miR-663 may play an impor-
tant role in ATRA-induced differentiation in HL-60
cells; however, the function of miR-663 and the
mechanism by which it affects HL-60 differentiation
requires further study.
Conclusion
Our study is the first investigation of the effect of ATRA
on microRNA expression, specifically the ability of
ATRA treatment to upregulate miR-663 expression and
lentiviral delivery of miR-663 can induce differentiation
and inhibit proliferation in HL-60 cells.
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